Vol. 2 No. 10 (2022)
Reimbursement Recommendations

Ruxolitinib (Jakavi)

Published October 3, 2022

Key Messages

  • CADTH recommends that Jakavi be reimbursed by public drug plans for the treatment of steroid-refractory or steroid-dependent acute graft-versus-host disease (aGvHD) if certain conditions are met.
  • Jakavi should only be covered to treat adults and pediatric patients aged 12 years and older who have steroid-refractory or steroid-dependent aGvHD.
  • Jakavi should only be reimbursed if prescribed by a specialist who has experience in the diagnosis and management of patients with aGvHD, and the cost of Jakavi is reduced.